New blood test to detect liver damage in under an hour

May 24, 2018, University College London
Credit: CC0 Public Domain

A quick and robust blood test that can detect liver damage before symptoms appear has been designed and verified using clinical samples by a team from UCL and University of Massachusetts.

The researchers say the test could address a huge need for early detection of as it distinguishes between samples taken from healthy individuals and those with varying degrees of damage.

A study, published today in Advanced Materials, describes the new method of detecting liver fibrosis, the first stage of liver scarring that leads to fatal liver if left unchecked, from a sample in 30-45 minutes.

"Liver disease is the third biggest cause of premature mortality in the UK, and one of the only leading causes of death that's on the increase. The major problem is that it's asymptomatic, meaning that it goes unnoticed until late stages of the disease when the damage is irreversible," said co-lead author Professor William Rosenberg (UCL Institute for Liver & Digestive Health).

Almost half of adults in Western countries face an elevated risk of liver disease due to overweight or heavy drinking but only a minority will develop serious liver damage.

"We hope that our new test could be used on a routine basis in GP surgeries and hospital clinics to screen people who face an elevated risk of liver disease, but don't yet show signs of liver damage to identify those with serious fibrosis, so that they can access treatment before it's too late. This may open the door to a cost-effective regular screening programme thanks to its simplicity, low cost and robustness," he said.

Researchers at the University of Massachusetts designed a sensor that uses large molecules called polymers, coated with fluorescent dyes that bind to blood proteins based on their chemical properties. The fluorescent dyes change in brightness and colour, yielding a different pattern of fluorescence depending on the protein composition of the blood .

The team at UCL tested the sensor by comparing results from small blood samples (equivalent to finger-prick checks) from 65 people, in three balanced groups of healthy patients and those with early-stage and late-stage fibrosis.

The groups were determined using the Enhanced Liver Fibrosis (ELF) test which is the existing benchmark for detection that requires samples to be sent away to a lab for analysis.

They found that the sensor could identify different patterns of protein levels in the blood serum of people in the three groups."By comparing the different samples, the sensor array identified a 'fingerprint' of . This method is known as a chemical nose, as it can recognise the difference between healthy and unhealthy blood samples without relying on known disease markers," said co-lead author Dr. William Peveler, who completed the research in the UCL Chemistry department before moving to the University of Glasgow.

"It's the first time this approach has been validated in something as complex as blood, to detect something as important as liver disease," he added.

The test could distinguish fibrotic samples from healthy samples 80% of the time, reaching the standard threshold of clinical relevance on a widely-used metric, and comparable to existing methods of diagnosing and monitoring fibrosis.

The test distinguished between mild-moderate fibrosis and severe 60% of the time. As this is only the first report of its use, the researchers are hopeful they can refine it to be more effective, and they will be testing it on much larger groups of patients.

"We are developing the test from being a lab-based to a point-of-care diagnostic and monitoring device that can be used in GP surgeries. This could take several more years but is particularly exciting as the technology has the potential to help millions of people access earlier care to prevent fatal liver disease," added Dr. Peveler.

The sensing strategy uses a 'signature'-based approach that is highly versatile. "A key feature of this sensing strategy is that it is not disease-specific, as it is applicable to a wide spectrum of conditions, which opens up the possibility of diagnostic systems that can track health status, providing both disease detection and the monitoring of wellness," said co-lead author Professor Vincent Rotello (University of Massachusetts Amherst).

Explore further: Family of patients with NAFLD and cirrhosis are at increased risk of liver fibrosis

More information: William J. Peveler et al, A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array, Advanced Materials (2018). DOI: 10.1002/adma.201800634

Related Stories

Family of patients with NAFLD and cirrhosis are at increased risk of liver fibrosis

June 19, 2017
Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by abnormal accumulation of fat in the liver. NAFLD is diagnosed in up to one in three adults and one in 10 children in the United States, and obesity ...

New guidelines aim to prevent medics from failing to diagnose patients with liver disease

December 20, 2017
New recommendations, led by experts at the University of Birmingham, have been published to improve the use of liver blood tests.

Changes in blood microbiota in obese with liver fibrosis

September 22, 2016
(HealthDay)—In obese patients, changes in blood microbiota are associated with liver fibrosis, according to a study published online Sept. 17 in Hepatology.

Altered microbiome linked to liver disease in adolescents with cystic fibrosis

February 18, 2015
A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis.

World-first discovery of protein that causes liver disease brings hope for new treatments

May 24, 2017
In a world-first discovery, scientists at Sydney's Westmead Institute for Medical Research have identified a protein that causes liver fibrosis (scarring), paving the way for new treatments for liver disease to be developed.

Many diabetics don't know they have serious liver disease

September 21, 2015
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. NAFLD is a frequent finding in patients with type 2 diabetes, but the exact prevalence of NAFLD, as well as whether patients ...

Recommended for you

Foods combining fats and carbohydrates more rewarding than foods with just fats or carbs

June 14, 2018
Researchers show that the reward center of the brain values foods high in both fat and carbohydrates—i.e., many processed foods—more than foods containing only fat or only carbs. A study of 206 adults, to appear June ...

3-D imaging and computer modeling capture breast duct development

June 14, 2018
Working with hundreds of time-lapse videos of mouse tissue, a team of biologists joined up with civil engineers to create what is believed to be the first 3-D computer model to show precisely how the tiny tubes that funnel ...

Beating cancer at its own game with a Trojan horse telomerase

June 13, 2018
Telomerase is a reverse transcriptase that uses an RNA template to synthesize telomeres. These repeat sequences bind special proteins that fold the ends of chromosomes back onto themselves to create a stable cap. When this ...

Turning the tables on the cholera pathogen

June 13, 2018
Recent cholera outbreaks in regions that are ravaged by war, struck by natural disasters, or simply lack basic sanitation, such as Yemen or Haiti, are making the development of new and more effective interventions a near-term ...

Troves from a search for new biomarkers: blood-borne RNA

June 12, 2018
It's the critical first step in treating everything from strokes to cancer: a timely and accurate diagnosis. Today, doctors often rely on biomarkers, such as cardiac troponin, the protein that appears in the blood after a ...

High-tech treatment of open leg wounds no better than using regular dressings: study

June 12, 2018
A new study of open leg fractures suggests there is no difference to patient recovery whether high-tech negative pressure wound therapy devices are used, compared to standard dressings.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.